Expert Consensus Survey: Prostacyclin Pathway Agent Use in Pulmonary Arterial Hypertension - Pulmonology Advisor

Expert Consensus Survey: Prostacyclin Pathway Agent Use in Pulmonary Arterial Hypertension - Pulmonology Advisor

Expert Consensus Survey: Prostacyclin Pathway Agent Use in Pulmonary Arterial Hypertension - Pulmonology Advisor

Posted: 05 Dec 2019 12:00 AM PST

A new consensus survey of expert opinions was published regarding the use of oral prostacyclin pathway agents in patients with various forms of pulmonary arterial hypertension (PAH) who received dual endothelin receptor antagonist (ERA)/phosphodiesterase type 5 inhibitor (PDE5i) therapy. The opinions were published in CHEST.

Researchers used MEDLINE to perform a systematic literature review of studies between 2008 and 2018 comprising adult patients with connective tissue disease (CTD)-associated PAH and function class (FC) 2 or 3 idiopathic, heritable, repaired congenital heart defect, or drug- or toxin-induced PAH (the latter was considered one etiologic grouping, IPAH+) who were treated with oral prostacyclin pathway agents. Pivotal trials for oral treprostinil and selexipag were also included if they focused on IPAH+ or CTD-associated PAH and FC 1 or 2 symptoms with background ERA/PDE5i therapy.

A series of clinical scenarios centered on 1 or the 3 etiologic groups (IPAH, CTD-associated PAH, and portopulmonary hypertension) were presented to the panelists for the development of the consensus. To create the consensus statements, the panel used the RAND/University of California Los Angeles Appropriateness Method, which incorporates the Delphi method and the nominal group technique.

A total of 458 case scenarios were accepted by Delphi 2. Based on the available data, the panelists agreed that selexipag may be considered for patients with IPAH+ and low- or intermediate-risk hemodynamic parameters who receive dual oral ERA/PDE5i therapy. This was specific to patients in FC 2 who had not been hospitalized for PAH in the past 6 months but had moderate to severe right ventricular dysfunction.

The panelists also agreed that intravenous or subcutaneous prostacyclin should be the treatment of choice in patients with IPAH+ or CTD-associated PAH who receive dual oral therapies and have high-risk hemodynamic parameters. Overall, a total of 14 consensus statements on the use of oral prostacyclin pathway agents that included 13 clinical scenarios where selexipag may be considered were discussed by the panelists.

Related Articles

A limitation of the survey included the paucity of evidence (only 5 clinical trials) regarding the use of selexipag and oral treprostinil.

Because of these limitations, the authors concluded that the "expert opinions must be validated with rigorous prospective studies, and this document may serve as a template for future investigations."

Disclosure: This clinical trial was supported by Actelion Pharmaceuticals. Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors' disclosures.

Reference

McLaughlin VV, Channick R, De Marco T, et al. Results of an expert consensus survey on the treatment of pulmonary arterial hypertension with oral prostacyclin pathway agents [published online November 16, 2019]. CHEST. doi:10.1016/j.chest.2019.10.043

Topics:

Pulmonary Arterial Hypertension Pulmonary Hypertension

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Dyspnea (Shortness of Breath): Causes, Symptoms & Treatment - my.clevelandclinic.org

Image
Overview Shortness of breath (dyspnea) is most commonly caused by heart or lung conditions. Other causes include anemia, anxiety, lack of exercise or living with obesity. What is dyspnea (shortness of breath)? Dyspnea (pronounced "DISP-nee-uh") is the word healthcare providers use for feeling short of breath. You might describe it as not being able to get enough air ("air hunger"), chest tightness or working harder to breathe. Shortness of breath is often a symptom of heart and lung problems. But it can also be a sign of other conditions like asthma, allergies or anxiety. Intense exercise or having a cold can also make you feel breathless. What are paroxysmal nocturnal dyspnea (PND) and sighing dyspnea? Paroxysmal nocturnal dyspnea (PND) is a feeling like you can't breathe an hour or two after falling asleep. Sighing dyspnea is when you sigh a lot after taking deep breaths in to try to relieve the feeling of dyspnea. What is the differ...
Read more

What to Expect During Pulmonary Embolism Recovery - Healthline

Image
What to Expect During Pulmonary Embolism Recovery - Healthline What to Expect During Pulmonary Embolism Recovery - Healthline Pulmonary Arterial Hypertension: Updates in Epidemiology and Evaluation of Patients - AJMC.com Managed Markets Network Right-Sided Heart Failure: Symptoms, Causes, and Treatments - Healthline Right sided heart failure: Symptoms, outlook, treatment - Medical News Today What to Expect During Pulmonary Embolism Recovery - Healthline Posted: 19 May 2021 12:00 AM PDT A pulmonary embolism (PE) is when a blood clot becomes stuck in the blood vessels of your lung. These clots typically begin in the leg and then break free and travel to the lung. The American Lung Association estimates that about 1 in 1,000 people in the United States experience a PE each year. A PE can be a serious or life threatening condition, which means receiving prompt medical treatment is vital. Treatment of a PE focus...
Read more